INVESTORS

Cancer immunotherapy drugs are by far the fastest-growing segment of the oncology drugs industry.

multimmune GmbH's cancer theranostics programs have been supported by investment from a number of sources:

• Technology Investment Fund Bayern III GmbH & Co. KG
• S-Refit AG / Sobera Capital GmbH)
• RAABE Verögensverwaltungs GmbH
• SilverSky LifeSciences GmbH
• Private investors